BridgeBio Pharma Q3 revenue more than doubles on Attruby sales and Bayer milestone

Overview

• U.S. biopharma firm's Q3 revenue more than doubled yr/yr, driven by Attruby sales and Bayer milestone

• Company posted Q3 operating loss as costs rose with commercialization and R&D investments

• Attruby growth led by more newly diagnosed patients starting treatment, boosting first-line share

Outlook

• BridgeBio expects U.S. launch of BBP-418 for LGMD2I/R9 upon FDA approval in November 2026

• Company anticipates U.S. launch of oral infigratinib for achondroplasia after February 2027 FDA decision

• Encaleret for ADH1 has a May 2027 PDUFA date; U.S. launch expected upon approval

Result Drivers

• ATTRUBY SALES GROWTH - Co said revenue increase was primarily driven by higher U.S. Attruby net product sales, with growth led by treatment-naïve segment and increased share of new patient starts

• BAYER MILESTONE - Co recognized a one-time $75 mln sales milestone from Bayer under license agreement, contributing to higher license and services revenue

• OPERATING COSTS - Higher selling, general and administrative expenses and increased R&D spending contributed to Q3 operating loss, reflecting investment in commercialization and late-stage product development

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $108.50, about 53.2% above its October 28 closing price of $70.82

Reuters Recommended Reads

• Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

• Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

• Oct 29 - Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)